​

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRTX Stock Forecast

Vertex Pharmaceuticals (VRTX) stock forecast, based on 54 Wall Street analysts, predicts a 12-month average price target of $483.00, with a high of $564.00 and a low of $414.00. This represents a 8.29% increase from the last price of $446.03.

$350 $400 $450 $500 $550 $600 High: $564 Avg: $483 Low: $414 Last Closed Price: $446.03

VRTX Stock Rating

Vertex Pharmaceuticals stock's rating consensus is Buy, based on 54 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 41 Buy (75.93%), 13 Hold (24.07%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 54 0 13 41 Strong Sell Sell Hold Buy Strong Buy

VRTX Price Target Upside V Benchmarks

TypeNameUpside
StockVertex Pharmaceuticals8.29%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2821
Avg Price Target$540.00$466.63$473.14
Last Closing Price$446.03$446.03$446.03
Upside/Downside21.07%4.62%6.08%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25118111132
Nov, 25217111132
Oct, 25217121-32
Sep, 25216121-31
Aug, 25216131133
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2025Morgan Stanley$564.00$461.4822.22%26.45%
Dec 03, 2025Terence FlynnMorgan Stanley$516.00$433.1519.13%15.69%
Nov 04, 2025RBC Capital$415.00$426.93-2.79%-6.96%
Nov 04, 2025Carter GouldCantor Fitzgerald$485.00$427.3013.50%8.74%
Nov 04, 2025Stifel Nicolaus$445.00$426.004.46%-0.23%
Nov 04, 2025Gena WangBarclays$414.00$426.00-2.82%-7.18%
Oct 10, 2025Morgan Stanley$438.00$413.935.81%-1.80%
Sep 25, 2025Leerink Partners$456.00$381.8719.41%2.24%
Aug 05, 2025Truist Financial$490.00$374.9830.67%9.86%
Aug 05, 2025Stifel Nicolaus$455.00$374.9821.34%2.01%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 05, 2025Morgan StanleyOverweightOverweighthold
Dec 03, 2025Morgan StanleyEqual-WeightOverweightupgrade
Nov 04, 2025Cantor FitzgeraldOverweightOverweighthold
Nov 04, 2025BMO CapitalMarket PerformMarket Performhold
Oct 02, 2025CitigroupBuyBuyhold
Sep 02, 2025Raymond JamesMarket Performinitialise
Aug 05, 2025UBSBuyBuyhold
Jun 17, 2025RBC CapitalSector PerformSector Performhold
May 07, 2025Wolfe ResearchOutperformPeer Performdowngrade
May 06, 2025Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $2 $9 $16 $23 $30 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.44$9.09$12.97$14.05$-2.08----
Avg Forecast$10.39$12.96$14.60$15.03$0.48$18.47$20.49$22.97$25.82
High Forecast$11.66$14.54$16.11$15.40$1.12$19.96$25.45$28.82$29.56
Low Forecast$9.84$12.26$13.86$14.65$0.06$16.67$17.06$19.12$24.25
Surprise %0.48%-29.86%-11.16%-6.52%-533.33%----

Revenue Forecast

$5B $8B $11B $14B $17B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.21B$7.57B$8.93B$9.87B$11.02B----
Avg Forecast$6.16B$7.50B$8.93B$9.86B$10.89B$11.77B$12.86B$13.94B$15.25B
High Forecast$6.74B$8.21B$9.64B$9.91B$10.97B$13.68B$12.87B$14.04B$16.94B
Low Forecast$5.91B$7.19B$8.58B$9.79B$10.85B$11.22B$12.85B$13.85B$14.53B
Surprise %0.72%0.97%-0.03%0.06%1.17%----

Net Income Forecast

$-1B $800M $3B $4B $6B $8B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.71B$2.34B$3.32B$3.62B$-535.60M----
Avg Forecast$2.19B$2.08B$2.40B$3.62B$153.32M$4.77B$4.87B$5.30B$6.73B
High Forecast$2.63B$2.50B$2.88B$4.34B$291.61M$5.20B$6.63B$7.51B$7.70B
Low Forecast$1.76B$1.66B$1.92B$2.90B$15.03M$4.34B$4.44B$4.98B$6.32B
Surprise %23.54%12.58%38.24%--449.33%----

VRTX Forecast FAQ

Is Vertex Pharmaceuticals stock a buy?

Vertex Pharmaceuticals stock has a consensus rating of Buy, based on 54 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 41 Buy, 13 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vertex Pharmaceuticals is a favorable investment for most analysts.

What is Vertex Pharmaceuticals's price target?

Vertex Pharmaceuticals's price target, set by 54 Wall Street analysts, averages $483 over the next 12 months. The price target range spans from $414 at the low end to $564 at the high end, suggesting a potential 8.29% change from the previous closing price of $446.03.

How does Vertex Pharmaceuticals stock forecast compare to its benchmarks?

Vertex Pharmaceuticals's stock forecast shows a 8.29% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vertex Pharmaceuticals over the past three months?

  • December 2025: 3.12% Strong Buy, 56.25% Buy, 34.38% Hold, 3.12% Sell, 3.12% Strong Sell.
  • November 2025: 6.25% Strong Buy, 53.12% Buy, 34.38% Hold, 3.12% Sell, 3.12% Strong Sell.
  • October 2025: 6.25% Strong Buy, 53.12% Buy, 37.50% Hold, 3.12% Sell, 0% Strong Sell.

What is Vertex Pharmaceuticals’s EPS forecast?

Vertex Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $18.47, marking a -987.98% decrease from the reported $-2.08 in 2024. Estimates for the following years are $20.49 in 2026, $22.97 in 2027, and $25.82 in 2028.

What is Vertex Pharmaceuticals’s revenue forecast?

Vertex Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $11.77B, reflecting a 6.80% increase from the reported $11.02B in 2024. The forecast for 2026 is $12.86B, followed by $13.94B for 2027, and $15.25B for 2028.

What is Vertex Pharmaceuticals’s net income forecast?

Vertex Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $4.77B, representing a -990.78% decrease from the reported $-536M in 2024. Projections indicate $4.87B in 2026, $5.3B in 2027, and $6.73B in 2028.